Nivolumab plus chemotherapy vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: 3-year follow-up from CheckMate 649

Yelena Y. Janjigian, MD, reviews the 3-year follow-up data from the CheckMate 649 trial investigating nivolumab plus chemotherapy as a first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma.

Video Player is loading.
Current Time 0:00
Duration 10:07
Loaded: 0%
Stream Type LIVE
Remaining Time 10:07
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

x